Skip to content

A randomized and controlled study of ruracidone in the treatment of bipolar depression in adolescents and early adulthood

A randomized and controlled study of ruracidone in the treatment of bipolar depression in adolescents and early adulthood

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049426
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-08-06
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bipolar disorder

Interventions

Experimental group:treatment with lurasidone
Control group:treatment with quetiapine

Sponsors

Beijing AnDing Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 24 Years

Inclusion criteria

Inclusion criteria: 1. After the patient has fully explained and understood the purpose, content, expected treatment and pharmacological effects and risks of the research, the patient and the legal representative voluntarily signed a written informed consent; 2. Outpatients aged 14 to 24 years; 3. Patients who are in line with bipolar disorder and currently have a depressive episode (diagnosed according to DSM-5 criteria); 4. At the time of enrollment, the current depressive episode >= 2 weeks; 5. Patients with MADRS total score >=22 and YMRS total score <=12 at screening and baseline; 6. For women of childbearing potential, patients with negative urine pregnancy tests at screening.

Exclusion criteria

Exclusion criteria: 1. Patients with a lifetime history of severe mental disorders or with symptoms consistent with severe mental disorders (except for bipolar disorder as defined by DSM-5); 2. Patients with MADRS item 10 (suicidal ideation) score >=4 at screening or baseline; 3. Patients who are considered by the investigator to be suicidal and at immediate risk of harming themselves or others, and those who answered "Yes" to item 4 or 5 of the C-SSRS at screening or baseline; 4. Patients using monoamine oxidase inhibitor (MAOI), fluoxetine, clozapine, any long-acting injection (sustained-release injection) antipsychotics within 21 days before screening; 5. Patients with clinically significant comorbidities in the past or at present, and the researchers believe that they are not suitable for participating in this trial.

Design outcomes

Primary

MeasureTime frame
Montgomery Asperger Depression Scale score;

Secondary

MeasureTime frame
Clinical general impression - bipolar disorder version severity scale score;sheehan disability scale score;Hamilton Anxiety Scale score;Young's Mania Rating Scale;Effective rate;complete remission rate;Abnormal Involuntary Movement Scale score;Simpson Angus scale score;Barnes Akathisia Rating Scale score;

Countries

Chia

Contacts

Public ContactWang Wei

Beijing AnDing Hospital, Capital Medical University

seeyou2008@163.com+86 13811120386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026